Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event
A male patient [age at onset not stated] exhibited treatment failure during treatment with acitretin and ciclosporin for DITRA related generalised pustular psoriasis [routes and dosages not stated].
The male patient had an early-onset deficiency of interleukin thirty-six receptor antagonist (DITRA) with frequently relapsing typical generalised pustular psoriasis (GPP) with systemic symptoms and a geographic tongue. He was prescribed adalimumab after treatment failure with acitretin and ciclosporin [cyclosporine]. Thereafter, he was in complete stable clinical remission for several months after withdrawal of adalimumab treatment. Later, at the age on 16 years (in September 2020), he had DITRA flare-up secondary to SARS-CoV-2 infection. He received treatment with betamethasone with partial improvement in GPP. A week later, SARS-CoV-2 detection was found to be negative. He was restarted on adalimumab treatment, leading to complete resolution of SARS-CoV-2-induced GPP flare without relapse over a 6 months follow-up period.
Reference
- Bozonnat A, et al. SARS-CoV-2 infection inducing severe flare up of Deficiency of Interleukin Thirty-six (IL-36) Receptor Antagonist (DITRA) resulting from a mutation invalidating the activating cleavage site of the IL-36 receptor antagonist. Journal of Clinical Immunology 41: 1511-1514, No. 7, 2021. Available from: URL: https://link.springer.com/article/10.1007%2Fs10875-021-01076-6 [DOI] [PMC free article] [PubMed]